Dexlansoprazole MUPS Pellets Manufacturer & Supplier
Multiparticulate pellets for flexible delayed-release formulation development in proton pump inhibitor programs.
Product overview
Dexlansoprazole MUPS formulations use multiple coated units rather than a single monolithic dosage form, allowing flexibility in capsule and other multiparticulate presentations. Rraynex applies controlled pelletization and coating processes to support consistent distribution, moisture management, and release behavior.
Key characteristics
- Multi-unit pellet system suitable for PPI formulation development.
- Controlled particle-size distribution.
- Gastro-resistant coating platform.
- Suitable for capsule and multiparticulate dosage forms.
- Technical support for formulation optimization and scale-up.
Product specifications
- Product
- Dexlansoprazole MUPS Pellets
- Form
- MUPS Pellets
- Therapeutic category
- Anti-Ulcerant (PPIs)
- Strength
- 20%
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies Dexlansoprazole MUPS Pellets to pharmaceutical manufacturers, formulation developers and CDMOs in 25/50 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all pellets Manufacturing capabilities
Other Dexlansoprazole products from Rraynex
- Dexlansoprazole — Pellets
- Dexlansoprazole DDR — Pellets